Back to top

Analyst Blog

OncoGenex Pharmaceuticals, Inc. (OGXI - Snapshot Report) recently announced that it has finished enrolling patients in its phase II study, Borealis-1, which is being conducted to evaluate the survival benefit, safety and tolerability of OGX-427 plus Eli Lilly & Company’s (LLY - Analyst Report) Gemzar and Platinol for the treatment of patients with advanced bladder cancer.

The randomized, placebo-controlled phase II study has enrolled roughly 180 patients who will be randomized to receive Gemzar, Platinol, and OGX-427 at two dose-levels (600 mg or 1000 mg) or Gemzar, Platinol and placebo.

While overall survival is the primary endpoint of the study, benefit/risk of the two dosages will be also evaluated using clinical benefit, safety and tolerability outcomes for each dose.

Data from the Borealis-1 study is expected in the second half of 2014.

Another study that is being conducted on OGX-427 for metastatic bladder cancer is Borealis-2. The Borealis-2 study is being conducted in patients suffering from advanced or metastatic bladder cancer whose disease has progressed following initial platinum-based chemotherapy treatment.

OncoGenex’ OGX-427 is in seven phase II studies, namely, Borealis-1, Borealis-2, Pacific, Spruce, OGX-427-PR01, Rainier and Cedar.

The Pacific study is evaluating the benefit of OGX-427 plus Zytiga in patients with castrate-resistant prostate cancer (CRPC). Patient enrollment is currently in progress. The Spruce study is being conducted for the treatment of previously untreated advanced non-squamous non-small cell lung cancer patients.

Rainieris designed to evaluate the survival benefit of adding OGX-427 to Celgene Corp.’s (CELG - Analyst Report) Abraxane plus Gemzar in previously untreated metastatic pancreatic cancer patients.

The Cedar study is evaluating OGX-427 as a first-line therapy in patients suffering from advanced squamous cell lung cancer.

OncoGenex carries a Zacks Rank #3 (Hold). Currently, Jazz Pharmaceuticals (JAZZ - Analyst Report) looks moreattractive with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 26.23 +7.10%
CENTURY ALU… CENX 26.54 +6.24%
TESLA MOTOR… TSLA 282.12 +4.61%
BAIDU ADS BIDU 222.77 +3.85%
RTI SURGICA… RTIX 5.51 +3.77%